Skylight Health Group Inc.

Skylight Health Group Inc. operates as a healthcare services and technology company in the United States, Canada, the United Kingdom, and Colombia. It operates the US multi-state primary care health network, which provides a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The company also owns and operates a proprietary electronic health record system that supports the delivery of care to patients through telemedicine and other remote monitoring system integrations. In addition, it offers a disruptive subscription-based telemedicine service for the un/under-insured population. The company was formerly known as CB2 Insights Inc. and changed its name to Skylight Health Group Inc. in November 2020. Skylight Health Group Inc. was founded in 2014 and is headquartered in Mississauga, Canada.

Skylight Health Group Inc. trades as SLHPF on OTC. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $27.16M of revenue and -$13.75M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Skylight Health Group Inc. can be compared against peers such as American Bio Medica Corporation, Acacia Diversified Holdings, Inc., Allied Healthcare Products, Inc., American CryoStem Corporation, DermTech, Inc., ER Urgent Care Holdings, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3,922, beta of -4.43, and return on equity of -36.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

SLHPF currently shows total debt of $16.19M and beta of -4.43. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.skylighthealthgroup.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.